Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer.

Introduction: The treatment strategy for castration-resistant prostate cancer (CRPC) has changed with the approval of several new agents. In 2011, abiraterone acetate was approved for the treatment of metastatic CRPC; however abiraterone is known to cause mineralocorticoid excess syndrome characterized by hypokalemia, fluid retention, and hypertension. We experienced two cases of grade 4 hypokalemia associated with abiraterone treatment.

[Prostate cancer in a young adult : a case report].

We report a case of prostate cancer in a 41-year-old male. The patient initially visited another institution with a chief complaint of left breech pain. He was referred to our hospital for further investigation.

[Abscess of corpus cavernosum: two case reports].

Case 1: A 50-year-old man was admitted to our hospital complaining of miction pain and fever up. Although there was remission by antibiotic treatment, symptoms recurred. Computed tomographic scan revealed swelling of scrotum and penis.